The company priced 3.7 million units of securities at $1.35 per share, according to an Oct. 7 news release.
Bone Biologics also granted underwriters the option to purchase up to 566,666 additional shares of common stock.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
